• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$7.51 $0.11 (1.49%)

REAL-TIME: Last trade at

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Chelsea: A Short-Term Buying Opportunity

A Much-Needed Win for Pfizer

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

The 2 Best-Performing Sectors Over the Last Decade

Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most

Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most

The New Pfizer: 6 Drug Companies With Bullish Short Trends

Mini J&J? I Guess Not

Better Late Than Never? Maybe.

Losing Biobucks as Pharma Reshuffles Its Deck

Mid-Day Update: Stocks Rally on Better-Than-Expected Jobs Report; Commodities Gain

Stocks Rally on New Jobs Data; Oil Adds Back Some of Prior-Session Loss

A Dedication to R&D Means These Stocks Could See Robust Growth

Pfizer Needs Rheumatoid Arthritis Drug to Keep Performing

6 Stocks Near Lows With Rising Call Volume

INTERVIEW: AstraZeneca R&D Chief Seeks Alliances, In-Licencing

Astra Launches Late-Stage Rheumatoid Arthritis Pill Trials

Analyst Calls: BMY, FSLR, GSK, LGF, MHS, PVH, SAI, SU, WAG, X ...

AstraZeneca Agrees License Deal With Rigel Pharmaceuticals

UPDATE 1-Rigel in pact with AstraZeneca for arthritis drug

Rigel sees partner for psoriasis drug in 3 months - COO

AstraZeneca, Rigel To Develop Rheumatoid Arthritis Treatment

UPDATE 1-Rigel to move arthritis drug forward; posts weak Q3